Erytech Pharma falls after cancer drug fails to extend patient survival

Phaxiam Therapeutics SA

25/10/2021 13:57

** French drug developer's U.S.-listed shares  ERYP.O  down
~30.8% at an all-time low of $3.79 premarket
    ** Co says lead drug failed in a late-stage study to meet
the main goal of extending survival in pancreatic cancer
patients whose cancer had spread with prior treatment 
    ** Co reiterates its plan to submit marketing application
for eryaspase in treating patients with a type of blood and bone
marrow cancer, by the end of this year
    ** Up to Friday's close, stock had fallen 40.63% YTD

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))